BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 19322959)

  • 1. Neuroprotection: a new strategy in the treatment of schizophrenia. Early detection and intervention.
    Perkins DO
    CNS Spectr; 2007 Oct; 12(10 Suppl 18):10-3. PubMed ID: 19322959
    [No Abstract]   [Full Text] [Related]  

  • 2. Neuroprotection: a new strategy in the treatment of schizophrenia. Treatment of first-episode psychosis.
    Buckley PF
    CNS Spectr; 2007 Oct; 12(10 Suppl 18):7-10. PubMed ID: 19322958
    [No Abstract]   [Full Text] [Related]  

  • 3. [Drug treatment of functional psychotic disorders].
    Bridler R; Umbricht D; Hell D
    Praxis (Bern 1994); 2001 May; 90(22):981-6. PubMed ID: 11450186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drugs for psychotic disorders.
    Treat Guidel Med Lett; 2010 Aug; 8(96):61-4; quiz two pages following last numbered page.. PubMed ID: 20651640
    [No Abstract]   [Full Text] [Related]  

  • 5. [Atypical antipsychotic agents in the adolescent: what implications for the future?].
    Cohen D
    Encephale; 2011 Sep; 37(4 Suppl 4):H15-7. PubMed ID: 22108183
    [No Abstract]   [Full Text] [Related]  

  • 6. Outcomes of an early psychosis intervention program.
    Pelosi AJ
    Aust N Z J Psychiatry; 2005 Jun; 39(6):522-3; author reply 523-4, 525-6. PubMed ID: 15943656
    [No Abstract]   [Full Text] [Related]  

  • 7. Brain volume changes in schizophrenia: how do they arise? What do they mean?
    Lewis DA
    Psychol Med; 2009 Nov; 39(11):1779-80. PubMed ID: 19379533
    [No Abstract]   [Full Text] [Related]  

  • 8. The effects of antipsychotics on brain structure: what have we learnt from structural imaging of schizophrenia?
    Borgwardt SJ; Smieskova R; Fusar-Poli P; Bendfeldt K; Riecher-Rössler A
    Psychol Med; 2009 Nov; 39(11):1781-2. PubMed ID: 19476691
    [No Abstract]   [Full Text] [Related]  

  • 9. ["Sluggish schizophrenia" (concerning the article by A.B. Smulevich and P.V. Mikhalev (S.S. Korsakov zhurnal nevropatologii i psikhiatrii, No. 12, l987, pp. 186-187].
    Aliev N
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1992; 92(2):132. PubMed ID: 1355941
    [No Abstract]   [Full Text] [Related]  

  • 10. New findings on antipsychotic use in children and adolescents with schizophrenia spectrum disorders.
    Ross RG
    Am J Psychiatry; 2008 Nov; 165(11):1369-72. PubMed ID: 18981065
    [No Abstract]   [Full Text] [Related]  

  • 11. [The significance of the early detection and intervention for schizophrenia].
    Takeshi K; Yamaguchi T; Mizuno M
    Nihon Rinsho; 2013 Apr; 71(4):630-4. PubMed ID: 23678591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Speech production in schizophrenia: preliminary data regarding voice onset time.
    Epstein-Lubow G; Hochstadt J; Lieberman P; Kaplan GB
    Schizophr Res; 2006 Feb; 82(2-3):267-9. PubMed ID: 16371248
    [No Abstract]   [Full Text] [Related]  

  • 13. Switching antipsychotic medications: a 2-year chart-review study exploring patient characteristics and psychiatric service use of schizophrenia patients.
    Schneider AL; Mosier KE; Tempier RP
    J Clin Psychiatry; 2009 Jun; 70(6):937-9. PubMed ID: 19573492
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacology and mechanism of action of existing and new neuroleptics.
    Niemegeers CJ
    Acta Psiquiatr Psicol Am Lat; 1990; 36(1-2):26-36. PubMed ID: 1981439
    [No Abstract]   [Full Text] [Related]  

  • 15. The CATIE study and its implications for antipsychotic drug use.
    Janicak PG
    Essent Psychopharmacol; 2006; 7(1):53-63. PubMed ID: 16989293
    [No Abstract]   [Full Text] [Related]  

  • 16. Metabolic disturbances associated with antipsychotic use.
    Newcomer JW
    J Clin Psychiatry; 2001; 62 Suppl 27():3-4; discussion 40-1. PubMed ID: 11806487
    [No Abstract]   [Full Text] [Related]  

  • 17. Neuroprotection: a therapeutic strategy to prevent deterioration associated with schizophrenia.
    Lieberman JA; Perkins DO; Jarskog LF
    CNS Spectr; 2007 Mar; 12(3 Suppl 4):1-13; quiz 14. PubMed ID: 17329984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment guidelines for non-schizophrenic psychotic disorders?].
    Jäger M; Frasch K; Weinmann S; Becker T
    Psychiatr Prax; 2007 Nov; 34(8):370-6. PubMed ID: 17806003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroprotection: a new strategy in the treatment of schizophrenia. Neurobiological basis of neurodegeneration and neuroprotection.
    Lieberman JA
    CNS Spectr; 2007 Oct; 12(10 Suppl 18):4-6. PubMed ID: 17934388
    [No Abstract]   [Full Text] [Related]  

  • 20. Improving outcome in schizophrenia: the case for early intervention.
    Malla AK; Norman RM; Voruganti LP
    CMAJ; 1999 Mar; 160(6):843-6. PubMed ID: 10189434
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.